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Summary
Background: Vitamin D deﬁciency has been associated with non-alcoholic fatty
liver disease (NAFLD). However, the role of polymorphisms determining vitamin D
status remains unknown.
Objectives: The objectives of this study were to determine in UK children with
biopsy-proven NAFLD (i) their vitamin D status throughout a 12-month period and
(ii) interactions between key vitamin D-related genetic variants (nicotinamide adenine
dinucleotide synthase-1/dehydrocholesterol reductase-7, vitamin D receptor,
group-speciﬁc component, CYP2R1) and disease severity.
Methods: In 103 paediatric patients with NAFLD, serum 25-hydroxyvitamin D
(25OHD) levels and genotypes were determined contemporaneously to liver biopsy
and examined in relation to NAFLD activity score and ﬁbrosis stage.
Results: Only 19.2% of children had adequate vitamin D status; most had mean
25OHD levels considered deﬁcient (<25 nmol·L1, 25.5%) or insufﬁcient
(<50 nmol·L1, 55.3%). Patients had signiﬁcantly lower 25OHD levels in winter
months (95% CI: 22.7–31.2 nmol·L1) when compared with spring (30.5–
42.1 nmol·L1; P = 0.0089), summer (36.3–47.2 nmol·L1; P < 0.0001) and au-
tumn (34.2–47.5 nmol·L1; P = 0.0003). Polymorphisms in the nicotinamide ade-
nine dinucleotide synthase-1/dehydrocholesterol reductase-7 (rs3829251,
rs12785878) and vitamin D receptor (rs2228570) genes were independently asso-
ciated with increased steatosis; while a group-speciﬁc component variant (rs4588)
was associated with increased inﬂammation in liver biopsies.
Conclusions: ChildrenwithNAFLD in theUKhaveparticularly lowwinter vitaminDsta-
tus, with vitamin D insufﬁciency prevalent throughout the year. Polymorphisms in the vita-
min D metabolic pathway are associated with histological severity of paediatric NAFLD.
Keywords: 25OHD, genotype, non-alcoholic fatty liver disease, vitamin D.
Abbreviations: NAFLD, non-alcoholic fatty liver disease; 25OHD, 25-
hydroxyvitamin D; BMI, bodymass index; AST, aspartate transaminase; ALT, alanine
transaminase; NAS, NAFLD activity score; SNPs, single nucleotide polymorphisms;
NADSYN1, nicotinamide adenine dinucleotide synthase-1; NASH, non-alcoholic
steatohepatitis; DHCR7, dehydrocholesterol reductase-7; GC, group-speciﬁc
component; VDR, vitamin D receptor; PNPLA3, patatin-like phospholipase
domain-containing protein 3
Introduction
A growing body of research suggests a relationship
between vitamin D deﬁciency and chronic liver dis-
ease, in particular non-alcoholic fatty liver disease
(NAFLD). With prevalence estimated up to 80% in
obese children, NAFLD is now the most common
chronic liver disease in the paediatric population and
fast becoming the most common indication for liver
transplantation (1). Although transplantation for
NAFLD in children is exceedingly rare, the histological
pattern of paediatric disease (type 2 non-alcoholic
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steatohepatitis, NASH) is associated with more severe
disease and possibly with a rapid rate of progression (2).
Despite the high prevalence of NAFLD however, its
molecular pathogenesis remains only partially under-
stood and targeting those who aremost likely to prog-
ress is difﬁcult. The development and progression of
the disease are presumed to bemultifactorial in nature
and inﬂuenced by both genetic and nutritional factors
(3). Lifestyle change is the only proven effective treat-
ment for paediatric NAFLD (4) and identifying those
at increased risk of progression may allow more
targeted individualized therapy. Recent studies have
demonstrated that low vitamin D status associates
with paediatric NAFLD independently of body mass
index (BMI) in Australian (5) and Italian (6) cohorts,
raising the question of whether improvement in vita-
min D status through diet or supplementation may
be beneﬁcial in some patients (7).
The most commonly used biomarker of vitamin D
status is 25-hydroxyvitamin D (25OHD), which is the
most stable circulating form of vitamin D and reﬂects
both dietary intake and cutaneous synthesis (8). In
the UK, 25OHD status is highest in the summer and
lowest during winter and spring months. Vitamin D
status has a strong hereditary component with dis-
tinct sets of common gene variants, explaining some
of the differences observed in vitamin D status be-
tween different ethnic populations (9,10). Given the
possible association between low vitamin D status
and NAFLD, and the hereditary component of vitamin
D status, the aims of this study were to determine in a
multi-ethnic cohort of children from the UK with
biopsy-proven NAFLD (i) their 25OHD status and ex-
tent of vitamin D deﬁciency/insufﬁciency throughout
a given 12-month period and (ii) interactions between
key polymorphisms related to vitamin D metabolism
and NAFLD disease severity.
Methods
Study design and patients
This observational study received ethical approval
from the UK National Research Ethics Service (09/
H0808/15) and was conducted according to the Hel-
sinki declaration. Anonymised clinical data were ex-
amined from patients who had attended a tertiary
paediatric liver centre (King’s College Hospital,
London, UK) between March 2001 and July 2013;
who had suspected NAFLD conﬁrmed by biopsy
and had buffy coat samples available. All patients in-
cluded were less than 19 years of age at sample col-
lection. Patients were excluded if taking vitamin D
supplementation or if NAFLD was not the primary liver
diagnosis. Other liver diseases were ruled out through
comprehensive clinical work up including abdominal
ultrasound, exclusion of viral hepatitis, Wilson disease
and inborn errors of metabolism including lysosomal
acid lyase deﬁciency. Liver biopsy was undertaken in
the case of persistently abnormal liver function tests
(>2 upper limit of normal aspartate transaminase
[AST] or alanine transaminase [ALT]) with a duration
over 6 months and/or an enlarged spleen (>1 cm
above upper limit of normal for age/height) on ultra-
sound on two or more occasions suggesting signiﬁ-
cant liver injury. Liver biopsies were formalin-ﬁxed
and parafﬁn-embedded. Sections were stained with
haematoxylin and eosin, orcein, Perl’s and reticulin.
Liver copper was also measured. Histological assess-
ment was performed by a single hepato-
histopathologist who was blinded to the patient’s clin-
ical details and scored according to the Kleiner/Brunt
system. Each biopsy was assigned a score for
steatosis (0–3), lobular inﬂammation (0–3), hepatocyte
ballooning (0–2) and ﬁbrosis (0–4), and the NAFLD ac-
tivity score (NAS) was calculated. BMI was calculated
by dividing weight, in kilograms by height, measured
with a ﬁxed stadiometer, in meters squared.
General biochemistry and measurement
of 25-hydroxyvitamin D
Liver enzymes and lipids were analysed using stan-
dard methods on the ADVIA 2400 analyser (Sie-
mens Healthcare Diagnostics, UK). Serum 25OHD
levels were measured only once due to low sample
volumes using a chemiluminescent immunoassay,
the ADVIA Centaur Vitamin D Total Assay. Samples
were coded, and the researcher was blinded to clin-
ical details. The sensitivity of the assay is estimated
to range from 10 nmol·L1 to 375 nmol·L1, while
the inter-assay variation was 4.2–11.9% and the
percentage of cross reactivity with vitamin D2 and
D3 was 1.1%. We used thresholds deﬁned by the
UK Department of Health (11) and the US Institute
of Medicine (8) for assessing vitamin D status;
25OHD concentrations below 25 nmol·L1 were
considered deﬁcient and below 50 nmol·L1 as in-
sufﬁcient, respectively.
Genotyping
Eight candidate polymorphisms were selected based
on their established inﬂuence on vitamin D status
(9,10,12) and/or liver disease (13,14). The variants in-
cluded two intronic single nucleotide polymorphisms
(SNPs) (rs12785878 and rs3829251) in the nicotin-
amide adenine dinucleotide (NAD) synthetase-1
(NADSYN1) gene, responsible for the ﬁnal step in the
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biosynthesis of NAD. The NADSYN1 gene is located
immediately proximal to the dehydrocholesterol
reductase-7 (DHCR7) gene on chromosome 11q12,
which encodes the rate-limiting enzyme responsible
for the reduction of 7-dehydrochlesterol to cholesterol
in the skin, making it unavailable for the synthesis of vi-
tamin D (10). There is sufﬁcient linkage disequilibrium
in the region that SNPs in NADSYN1 could be mark-
ing genetic variation in DHCR7, and both of these
SNPs have been reported associated with serum
25OHD levels in population studies (9,15). In addition,
we genotyped three SNPs, one intronic and two non-
synonymous, in the group-speciﬁc component (GC)
gene, which encodes the vitamin D binding protein,
the carrier of 25OHD in serum: rs2282679, rs7041
and rs4588. Polymorphisms in the cytochrome P450,
family 2, subfamily R, member 1 (CYP2R1) gene,
responsible for the ﬁrst hydroxylation of vitamin D to
25OHD in the liver (rs10741657), and the vitamin
D receptor (VDR) gene, involved in the nuclear trans-
portation of vitamin D (rs2228570), were also investi-
gated. Additionally, the polymorphism that has been
most commonly identiﬁed associated with NAFLD,
the patatin-like phospholipase domain-containing
protein 3 (PNPLA3) variant rs738409, was included
(13,14).
Genomic DNA was extracted from buffy coats, and
immediately stored at80°C. Probe primer sets were
designed by Applied Biosystems (Paisley, UK), and
genotyping assays were run on an ABI7500 real time
instrument (Applied Biosystems) using allelic discrim-
ination through the measurement of allele-speciﬁc
ﬂuorescence. All samples were run in duplicate with
positive and no-template controls; reproducibility
was >99%.
Statistical analysis
Statistical analyses were performed using SPSS v22
(IBM corporation, Armonk, New York) and Prism v7
(GraphPad Software Inc., California). Signiﬁcance
was set at a threshold of P-value ≤0.05. Data were
checked for normality using the D’Agostino and Pear-
son omnibus normality test, and outliers identiﬁed by
the ROUT test. Allele and genotype frequencies were
tested for consistency with Hardy–Weinberg equilib-
rium, and the chi-squared test was used to test the
distribution of categorical variables between different
genotypes and presented as speciﬁc percentages.
25OHD levels were evaluated by Independent two-
tailed t-test. Ethnicity was classiﬁed as Caucasian
and Non-Caucasian due to low frequencies in other
categories. Serum 25OHD levels were transformed
using the equation of Sachs (16) and predicted
August values were used for all comparisons. We
have estimated that for this cohort (n = 103), consid-
ering an α error = 0.05 and SD = 19.33 nmol·L1 in
serum vitamin D levels, we had a power of >80% to
detect a difference of 5.34 nmol·L1 within this group.
Linear regression analysis was used for analysing the
association between biochemical variables and the
strength of the association was reported as
correlation coefﬁcient (r). For multiple linear regression
with interaction analysis, a two-way ANOVA test of
unbalanced designs with interaction was performed
to examine for interaction between 25OHD levels,
genotype and histology, employing the Benjamini and
Hochberg method to calculate an adjusted P-value.
Results
Study population
A total of 103 paediatric patients with NAFLD were
enrolled in this observational study, and complete liver
histology was available for 73 (patient ﬂow diagram:
Fig. S1). Patients were predominantly male (66%)
and Caucasian (70%) with a median and (interquartile
range) age of 13.8 (11.3, 15.7) years. Non-Caucasians
were from a diverse mix of ethnic backgrounds but
predominantly from the Indian sub-continent. Patients
were usually overweight or obese for age, with a BMI
z-score of 2.1 (1.7, 2.3); while ALT levels were 57
(30, 80) IU·L1. Population characteristics including
liver histological features are summarized in Table 1.
Vitamin D status
Patients had low vitamin D status in general, with the
majority (80.8%) having mean serum 25OHD levels
below the ‘insufﬁcient’ threshold (<50 nmol·L1) and
25% having 25OHD levels below the ‘deﬁcient’
threshold (<25 nmol·L1). Cycling of 25OHD levels
throughout the year was evident; patients had signiﬁ-
cantly lower 25OHD levels in winter months (mean
[95%CI] nmol·L1: 26.9 [22.7–31.2]) when compared
with spring (36.3 [30.5–42.1]; P = 0.0089), summer
(41.8 [36.3–47.2]; P < 0.0001) and autumn (40.8
[34.2–47.5]; P = 0.0003) months (Fig. 1a). Therefore,
in order to normalize for seasonality, samples were
modelled using a recently published algorithm (16) to
provide predicted August values, which were used in
further comparisons (Fig. S2). In line with the pub-
lished literature (17), non-Caucasian patients had sig-
niﬁcantly lower mean 25OHD serum levels than
Caucasian patients (mean [95%CI] nmol·L1: 35.9
[30.1–41.7] vs. 40.7 [38.0–43.4], respectively,
P = 0.0188; Fig. S3).
Vitamin D-related polymorphisms in NAFLD | 3
© 2018 The Authors. Pediatric Obesity published by John Wiley & Sons Ltd
on behalf of World Obesity Federation
Pediatric Obesity
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
Caucasian patients with low NAS scores (≤2)
tended to have higher levels of 25OHD when com-
pared with patients with the highest NAS scores
(≥5), although this did not reach signiﬁcance due
to few patients with low NAS scores in our cohort
(P = 0.0531; Fig. 1b). There was a signiﬁcant lower
mean 25OH vitamin D level found in all children with
a NAS score ≥ 5 when compared with those with a
NAS score < 5, (P = 0.04; Fig. 1c). In Caucasian
children only, there was a clear trend to lower vita-
min D levels in those with NAS ≥5 vs. NAS ≤2
although this did not meet statistical signiﬁcance
(P = 0.06; Fig. 1d).
There were no differences in vitamin D levels found
in those with mild (F < 2) vs. signiﬁcant ﬁbrosis
(F ≥ 2) in either the group as a whole (Fig. 1e) or in
Caucasian patients only (Fig. 1f). The associations be-
tween serum 25OHD levels and weight, BMI, liver en-
zymes ALT, AST and GGT, and cholesterol were
assessed. BMI showed a moderate inverse correla-
tion with 25OHD levels (r = 0.420, P = 0.005; Fig.
S4A) while cholesterol levels showed a mild inverse
Table 1 Population characteristics1
All participants (n = 103) Caucasian (n = 72) Non-Caucasian (n = 25)
Age (years) 13.8 (11.3, 15.7) 13.8 (11.3, 15.6) 12.3 (9.8, 15.6)
Sex (% male) 66 63 72
Weight (kg) 79.3 (63.8, 102.6) 79.3 (63.8, 102.6) 59.2 (51.2, 77.7)
Height (cm) 164.2 (156.5, 176.8) 164.2 (156.5, 176.8) 159.1 (145.0, 164.5)
BMI (kg/m2) 29.3 (25.8, 32.2) 29.3 (25.7, 32.2) 25.8 (24.3, 29)
BMI centile 98 (95, 98) 98 (95, 98) 98 (95,98)
BMI z-score 2.1 (1.7, 2.3) 2.1 (1.7, 2.3) 2.0 (1.7, 2.2)
Cholesterol (mmol·L1) 4.3 (3.6, 4.9) 4.3 (3.6, 4.9) 4.4 (3.8, 4.6)
Triglycerides (mmol·L1) 1.4 (0.9, 2.3) 1.4 (0.9, 2.3) 1.8 (1.5, 2)
ALT (IU) 57 (30, 80) 57 (30, 80) 28 (21, 43)
AST (IU) 40 (30. 57) 40 (30, 57) 36 (26, 55)
GGT (IU) 26 (19, 40) 26 (19, 40) 22 (17, 25)
Histology
Steatosis
1 25 17 8
2 11 11 0
3 43 33 10
Lobular Inﬂammation
0 16 13 3
1 51 40 9
2 12 8 6
Ballooning
0 19 17 2
1 26 21 5
2 34 23 11
Fibrosis
0 3 3 0
1 23 16 7
2 22 21 4
3 31 24 7
NAS
1,2 9 8 4
3,4 31 24 7
5,6,7 39 37 7
1Expressed as median (IQR) or % (sex).
Abbreviations: kg, kilogram; IQR, interquartile range; mmol·L
1
, millimole per litre; ALT, alanine transaminase; AST, aspartate transaminase; GGT, gamma
glutamyl transferase; NAS, NAFLD activity score.
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correlation with 25OHD levels (r =0.294, P = 0.018;
Fig. S4B).
Association of genetic variants with liver
histology
Caucasian allele frequencies for all SNPs examined in
this study (Table S1) were comparable with those re-
ported for HapMap European sample population, ex-
cept for PNPLA3 rs738409, where the G allele
showed lower prevalence in the general population
than in patients with NAFLD (minor allele frequency
0.23 in HapMap vs. 0.44 for children with NAFLD).
No deviation from Hardy–Weinberg equilibrium was
detected (P < 0.05 for all genotypes).
In Caucasian patients, presence of the G allele in
PNPLA3 (rs738409) was strongly associated with se-
verity of steatosis (P = 0.0125; Fig. 2a). Similarly, the
NADSYN1/DHCR7 gene variant rs12785878 G allele
(P = 0.0104; Fig. 2b) and NADSYN1/DHCR7
rs3829251 A allele (P = 0.0451; Fig. 2c), and VDR
rs2228570 A allele (P = 0.0121; Fig. 2d) were all asso-
ciated with severity of steatosis using the chi-squared
test. The PNPLA3 G allele was also associated with
presence of inﬂammation on biopsy (P = 0.0264;
Fig. 2e) as was the GC variant rs4588 (P = 0.0282),
causing a base change of C> A, (Fig. 2f). The remain-
ing variants did not show any statistically signiﬁcant
association with steatosis or inﬂammation. There
were no associations between any of the gene vari-
ants examined and histological ballooning or ﬁbrosis.
In a two-way ANOVA test of unbalanced designs with
interaction analysis and accounting for multiple
hypothesis testing, no strong interactions between
25OHD levels, genotype and histology were
observed.
Discussion
To our knowledge, this is the ﬁrst report to examine
the relationship between vitamin D status, genetic var-
iants known to affect vitamin D status and NAFLD his-
tological severity in a paediatric population. The
majority of children in this cohort had insufﬁcient vita-
min D levels throughout the year, with severe vitamin
D deﬁciency during the winter months. The average
serum 25OHD level in August in this patient group
was 44.1 nmol·L1, considerably lower than the
60.1 nmol·L1 average found in the 2470 UK adoles-
cents within the Avon Longitudinal Study of Parents
and Children (18). While we used conservative cut-
offs to deﬁne deﬁciency and insufﬁciency here, it is im-
portant to note that these have been deﬁned based
on skeletal effects of vitamin D, and serum OHD levels
Figure 1 Serum 25OHD levels and histological grading. (a)
Independent and repeated measures of serum 25OHD
levels of cohort. Dashed lines shows accepted thresholds
for deﬁciency (red) and insufﬁciency (green). (b) In Caucasian
patients, Brunt/Kleiner NAS grading vs. predicted August
25OHD status demonstrates lower levels in patients with
more severe disease using standard cut-offs for simple
steatosis (score 0–2), Borderline NASH (3–4) and NASH
(5–8). (c) Utilizing a score of <5 and ≥5 to deﬁne severity
of disease, those with less severe disease had signiﬁcantly
lower 25OHD in the group as a whole, with a similar trend
in Caucasian patients only (d). Fibrosis grading vs. predicted
August 25OHD status in all patients (e) and Caucasian pa-
tients (f) are shown. 25OHD levels are expressed around
the mean ± 95% CI; data were tested for normality using
the D’Agostino and Pearson omnibus normality test and
analysed using an unpaired t-test. 25OHD, 25-
hydroxyvitamin D; NASH, nonalcoholic steatohepatitis.
Vitamin D-related polymorphisms in NAFLD | 5
© 2018 The Authors. Pediatric Obesity published by John Wiley & Sons Ltd
on behalf of World Obesity Federation
Pediatric Obesity
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
associated with protective immunological effects are
considerably higher (90–100 nmol·L1) (19). Patients
in our cohort showed an inverse correlation between
both BMI and cholesterol and 25OHD levels similar
to a previous report (20). Multiple factors have been
implicated in the hypovitaminosis D typically ob-
served in obesity, including reduced dietary intakes
and decreased conversion pre vitamin D to active
vitamin D metabolites secondary to sequestration
of the fat-soluble vitamin in excess adipose tissue
(20). Importantly, and consistent with recently
published data from an Italian paediatric cohort (6),
serum 25OHD levels were found to be signiﬁcantly
lower in patients with more severe NAFLD as de-
ﬁned by NAS.
This contrasts with a recent report on adult patients
with NAFLD by Patel et al. that showed no relationship
with vitamin D levels, or the hepatic expression of
genes involved in vitamin D metabolism, and pres-
ence or severity of NAFLD. (21) Other studies in adult
patients with NAFLD have shown conﬂicting results,
some demonstrating a correlation between NAFLD
and nonalcoholic NASH severity, with lower levels of
vitamin D (22) and some not showing any association
(23). A meta-analysis including 974 adult patients did
not show an association between vitamin D (25OHD)
levels and NAFLD (24). Vitamin D levels alone are nec-
essarily variable, and the degree to which they vary
over the several decades in which NAFLD may prog-
ress is unknown. Indeed, recent work shows genetic
variation determines serum levels of vitamin D binding
protein thereby inﬂuencing the levels of bound and
‘free’ or bioavailable 25OHD (25). A limitation to our
study is that, similar to the genome-wide association
studies, total 25OHD levels were measured in serum
and we cannot account for bioavailability here. Like-
wise, hepatic expression of genes responsible for vita-
min D metabolism may well be altered or switched off
in the context of signiﬁcant liver injury. Genetic sus-
ceptibility to vitamin D alteration, either in absorption,
conversion to the active form or its availability are all
potential confounders to interpreting serum 25OHD
Figure 2 Histological scoring for steatosis in Caucasian patients in relationship to genotype for (a) PNPLA3 rs738409,
(b) NADYSN1/DHCR7 rs12785878, (c) NADSYN1/DHCR7 rs3829251 and (d) VDR rs2228570. Histological scoring for
inﬂammation in the same population in relationship to genotype for (e) PNPLA3 and (f) GC rs4588. All data are
representative of population percentages and were assessed by chi-squared test. DHCR7, dehydrocholesterol
reductase-7; GC, group-speciﬁc component; NADSYN1, nicotinamide adenine dinucleotide synthase-1; PNPLA3,
patatin-like phospholipase domain-containing protein 3; VDR, vitamin D receptor.
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levels; the measurement of effects on the end-
receptor may be more consistent.
We examined candidate polymorphisms in genes
involved in the vitamin D metabolic pathway that had
previously been identiﬁed by genome-wide associa-
tion or population studies as associated with either vi-
tamin D status or liver disease. Our results show that,
in Caucasian children with biopsy-conﬁrmed NAFLD
in the UK, variants of the NADSYN1/DHCR7
(rs12785878, rs3829251) and VDR (rs2228570)
genes are independently associated with increased
steatosis, while a GC variant (rs4588) was associated
with increased inﬂammation. Interestingly, this rs4588
SNP inﬂuences the serum level of vitamin D binding
protein, which was not measured here and may dra-
matically inﬂuence the amount of bioavailable hor-
mone (25). On the other hand, no associations were
found between a variant in the CYP2R1 gene
(rs2228570) and two other variants of the GC gene
(rs2282679 and rs7041). In line with reports in Amer-
ican and Italian paediatric NAFLD cohorts (13,14), we
found presence of the risk (G) allele for the PNPLA3
rs738409 variant was associated with increased
steatosis and inﬂammation scores. However, we
found no signiﬁcant associations between our investi-
gated SNPs in the vitamin D metabolic pathway and
serum 25OHD levels that have previously been re-
ported in other populations (9,15). This could be a re-
ﬂection of the ethnically heterogeneous population
studied and/or the small sample size.
Nicotinamide adenine dinucleotide synthase-1 en-
codes the enzyme responsible for the ﬁnal step in
the biosynthesis of NAD, which is used in the produc-
tion of cholesterol in the skin from 7-
dehydrocholesterol, making it unavailable for the vita-
min D synthetic pathway (15). It is in such close prox-
imity to the DHCR7 gene, which encodes the rate-
limiting enzyme responsible for the reduction of 7-
dehydrochlesterol to cholesterol in the skin, that the
polymorphisms studied here (rs12785878 and
rs3829251) may inﬂuence the function of either gene.
In our study, patients presenting with at least one
copy of either rare variants showed increased
steatosis grading. Thus, NADSYN1/DHCR7 may play
a role in development of NAFLD, and previously, the
rs12785878 rare allele has been increased liver stiff-
ness as assessed by transient elastography (26). Al-
though these SNPs have been associated with
decreased circulating 25OHD concentrations, when
examining this genotype against 25OHD status in
our study, results were likely confounded by small fre-
quency of the rare genotypes and limited size of our
cohort relative to population studies, restricting the
conclusions that can be drawn.
In a similar manner, the GC gene encodes the vita-
min D binding protein, which is synthesized in the liver
and is responsible for the binding and transport of vi-
tamin D and its metabolites (15). The most widely
studied SNPs include rs4588 and rs7041, which are
11 base pairs apart from one another, described as
being in moderate linkage disequilibrium and shown
to be consistently associated with 25OHD status.
However, in this present study, no SNPs in the GC
gene were associated with lower 25OHD status. This
could be due to the small sample size or different eth-
nic groups. Interestingly, SNP genotyping in our study
did demonstrate increased inﬂammation grade in the
presence of the rs4588 A allele. Relatedly, previous
study of the expression of VDR in patients with NASH
identiﬁed an inverse correlation with steatosis severity,
lobular inﬂammation and the NAS (27). Our study
shows an association between presence of the
rs2228570 risk allele and increased steatosis.
By analysing both serum levels and known variants
that may contribute to the metabolism and action of
vitamin D, this study attempts to deﬁne some of those
who may have a susceptibility to NAFLD at a young
age. The antiﬁbrotic effects of vitamin D in human he-
patic stellate cells have previously been demonstrated
(28), and a valid question is whether vitamin D treat-
ment may have anti-ﬁbrotic therapeutic potential in
paediatric NAFLD (7). While the efﬁcacy of vitamin D
supplementation on endothelial function in obese chil-
dren has recently been examined (29), studies with
liver endpoints are lacking. The limitations of this study
need to be addressed in future research. The sample
size was limited to a relatively small number of patients
who had undergone liver biopsy. Signiﬁcantly, greater
numbers are likely to be required to detect some of
the more modest associations with various variants.
Obese controls are not included in the study
although HAPmap is used to determine population
frequencies of the variants. Additionally, patient and
family sociodemographic details and deprivation
index were not investigated; these are potential con-
founding factors for body mass and 25OHD levels in
children (30) and would be useful for future studies.
Levels of vitamin D were normalized to August values,
and comparison is made with children from the Avon
Longitudinal Study of Parents and Children but not
matched for BMI. Levels of vitamin D are necessarily
cross-sectional and are likely to be dynamic, and so
an attempt is made with this study to describe under-
lying susceptibilities to the development and progres-
sion of liver injury via vitamin D metabolism rather than
rely on levels alone to explain disease.
This is the ﬁrst study conducted in a UK paediatric
population to ﬁnd a relationship between genetic
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variations in the vitamin Dmetabolic pathway and liver
histology severity. While the sample size and limited
number of candidate polymorphisms investigated
are potential limitations, liver biopsy is the criterion
standard to deﬁne NAFLD and histological analysis
is essential to stage disease. In addition, paediatric
NAFLD has distinct histological differences to adult
NAFLD including the distinction between type 1 and
type 2 NASH, and ﬁndings in the adult population
cannot be simply translated to children.
In conclusion, UK paediatric patients with NAFLD
have extremely low winter vitamin D status, with vita-
min D insufﬁciency prevalent throughout the year.
Polymorphisms in the vitamin D metabolic pathway
were associated with histological severity in patients
with NAFLD. These data suggest a possible genetic
link/consequence of vitamin D status on disease se-
verity, although a possible inﬂuence of the presence
of steatosis/inﬂammation on vitamin D metabolism
needs also to be considered. Although supplementa-
tion with vitamin D has not been demonstrated an ef-
fective intervention in the limited studies performed in
adult patients with NAFLD to date, further research is
warranted into whether targeted supplementation in
paediatric populations may be indicated.
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Figure S1. Participant data analysis ﬂow diagram
Figure S2:Modelled population 25(OH)D levels using
Sachs algorithm. Data are presented as mean ± 95%
CI. n = 71 for each month.
Figure S3. August 25(OH)D serum levels in Cauca-
sian and Non-Caucasian patients. Data are
expressed around the mean. Data were tested for
normality using the D’Agostino & Pearson omnibus
normality test and analysed using Mann–Whitney test.
Figure S4. BMI and serum cholesterol levels in Cau-
casian patients. BMI (A; n = 45) and serum cholesterol
levels (B; n = 65) versus 25(OH)D levels. Data were
tested for normality using the D’Agostino-Pearson
omnibus normality test and Spearman correlation
was performed demonstrating a weak but signiﬁcant
inverse correlation.
Table S1. Genotype distributions
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